Bra-line fat: It's a thing, and Allergan's studying Kybella as a remedy

Allergan CEO Brent Saunders
Allergan CEO Brent Saunders

Allergan ($AGN) thinks facial injectable Kybella has the potential to one day bank Botox-level sales. And the company is starting up a couple new studies to help it get there.

The Dublin drugmaker is initiating trials of the med in bra-line fat and fat around the knees and ankles, Bernstein analyst Ronny Gal wrote in a recent note to clients. And it’s hoping those will eventually help it add some new indications to the mix, on top of Kybella’s current approval for busting chin fat.

Kybella is a key growth driver for Allergan, which recently sold off its generics unit to Teva ($TEVA) and--not long before that--watched its Pfizer ($PFE) megamerger collapse at the hands of the U.S. Treasury.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The way CEO Brent Saunders describes it, Allergan’s aesthetic strategy is “owning the face”--and Allergan expects Kybella to “serve as a gateway to the lower face,” commercial chief Bill Meury told investors on the company’s Q2 conference call. It expects that strategy to open up a new market of consumers--including males.

And the way Allergan sees it, if the new Kybella indications eventually pan out--the way they have for blockbuster Botox, which treats everything from wrinkles to migraines--Kybella could “over time” become as large as the pharma’s star seller.

So far, everything’s going according to plan, Meury said on the call. Allergan has successfully capped off the first phase of Kybella’s launch--training more than 90% of the key injectors in the U.S.--and physician education is well underway.

Next up? “We are creating awareness and demand among consumers, which will be boosted by our DTC campaign beginning this month,” he said.

- read the call transcript

Special Report: The 25 most influential people in biopharma in 2015 - Brent Saunders - Actavis | The top 10 advertisers in Big Pharma

Related Articles:
Allergan plots DTC, label expansions for chin-fat buster Kybella
Allergan launches $10B buyback, focuses on tuck-in deals
Pfizer's $160B megadeal for Allergan collapses under new tax rules
With Allergan's Kybella campaign, Khloé Kardashian follows sister Kim into pharma land
Can Allergan make double-chin drug pay off? Maybe, but slowly, analysts say
Allergan extends deal spree with $2.1B Kythera buyout

Read more on

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.